Long‐term real‐world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all‐trans retinoic acid without chemotherapy—a retrospective, single‐centre study

Shifting gears to differentiation agents in acute promyelocytic leukemia with resource constraints—a cohort study

(2022) Tejasvini Vaid et al.   ACTA ONCOLOGICA

Early mortality continues to be a barrier to excellent survival in childhood acute promyelocytic leukemia: a retrospective study of 62 patients spanning 17 years

(2022) Pritam Singha Roy et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?

(2021) Prajwal Dhakal et al.   LEUKEMIA & LYMPHOMA

‘FLT3-ITD Mutation Does Not Influence Survival Outcome in Adult Acute Promyelocytic Leukemia Patients Treated With ATO and ATRA-Based Therapeutic Regimen: Experience From a North Indian Tertiary Care Centre’

(2021) Riju Rani Deka et al.   Clinical Lymphoma Myeloma & Leukemia

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

(2020) Jeffrey E. Lancet et al.   Blood Advances

Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide

(2019) Aniket Bankar et al.   BRITISH JOURNAL OF HAEMATOLOGY

Outcomes in Adult Acute Promyelocytic Leukemia: A Decade Experience

(2019) Rajani Priya Yedla et al.   Clinical Lymphoma Myeloma & Leukemia

Early detection of differentiation syndrome by chest ultrasound in acute promyelocytic leukaemia

(2018) Parathan Karunakaran et al.   BRITISH JOURNAL OF HAEMATOLOGY